Gastric Inhibitory Polypeptide Receptor - Pipeline Review: Anti-Obesity Agents Receive Green Signal in North America and Europe
Gastric inhibitory polypeptide receptor (GIPR) induces energy accumulation in adipose tissue in vitro. Nonetheless, gastric inhibitory polypeptide receptor becomes instrumental in lipid metabolism and is linked with insulin resistance and obesity. Several anti-obesity agents including sibutramine, orlistat and rimonabant have received green signal for clinical use in North America and Europe. GIP was initially identified as an activity in extracts which showed inhibited gastric acid secretion and gastrin release. Subsequently, gastric inhibitory polypeptide receptor exhibited to spur insulin release in...
View full press release